期刊文献+

反思与应对:AI医疗的伦理与法律风险 被引量:3

Reflection and Implication of Ethical and Legal Challenges of Medical AI
下载PDF
导出
摘要 科学技术的发展和人类对于生命健康的需求推动人工智能(AI)医疗的迅速发展。目前,有关AI医疗的评价莫衷一是。囿于医学本质的特殊性,要发挥AI医疗的理想效能,使其能真正造福人类,有必要对其风险作出预判和防范。AI医疗的不确定性风险凸出表现为对当前医患关系中医疗人员主体性的消解、大数据对患者乃至国家安全方面的潜在风险、准入领域制度的空白地带或造成法律责任界定不清等方面问题,通过伦理原则建构、人才培养和制度规约可以有效应对其风险,确保AI医疗成为“善智”。 Considerable advances in science and technology have provided a potential to the rapid development of artificial intelligence(AI)in medicine,thus meeting human needs for health.However,there is no convergence in the assessment of medical AI.Given the particularity of medical service,risk predictions and precautions are indispensable for medical AI intended to benefit mankind.Herein,an issue against the uncertainty risks of medical AI is proposed.We attempt to wellstandardize the development and application of medical AI technology in subjectivity,ethics and institution levels.
作者 吴蓓 陆树程 WU Bei;LU Shu-cheng(College of Marxism,Soochow University,Suzhou 215123,Chin)
出处 《医学与哲学》 2019年第21期9-13,共5页 Medicine and Philosophy
基金 2015年江苏高校哲学社会科学基金项目(2015SJB615) 2018年国家社会科学基金项目(18BKS042)
关键词 人工智能医疗 医学人文精神 医学伦理 法律责任 medical artificial intelligence medical humanities medical ethics legal liability
  • 相关文献

参考文献11

二级参考文献77

  • 1Wang C, Cao B, Liu QQ, et al. Oseltamivir compared withthe Chinese traditional therapy maxingshigan-yinqiaosanin the treatment of HjNj influenza: a randomized trialfj].Ann Intern Med, 2011, 155(4):217-225.
  • 2Li X, Zhang J, Huang J, et al. A multicenter, randomized,double-blind, parallel-group,placebo-controlled study ofthe effects of qili qiangxin capsules in patients with chronicheart failure[J]. J Am Coll Cardiol, 2013, 62(12):1065-1072.
  • 3Shang H, Zhang J, Yao C, et al. Qi-shen-yi-qi drippingpills for the secondary prevention of myocardial infarction:a randomised clinical trial[J]. Evid Based ComplementAltemat Med, 2013, 2013:738391.
  • 4Phase II multi-center study of T89 to treat chronic stableangina (T89 phase 2)[EB/OL].(2012-12-10) [2015-06].https://www.clinicaltrials.gov/ct2/show/NCT00797953?term=tasly&rank=6.
  • 5Phase III trial of Dantonic? (T89) Capsule to prevent and treatstable angina (CAESA) [EB/OL]. (2015-05-19) [2015-06].https://www.clinicaltrials.gov/ct2/show/NCT01659580?term=tasly&rank=3.
  • 6Assess the antifibrotic activity of Fuzheng Huayu in chronichepatitis C patients with hepatic fibrosis[EB/OL]. (2014-06-18)[2015-06]. https://www.clinicaltrials.gov/ct2/show/study/NCT00854087?cond=hepatic+fibrosis&spons=shanghai&rank=3.
  • 7Efficacy and safety study of lipid-lowering effects ofXueZhiKang (XZK) in patients with hyperlipidemia[EB/0L].(2014-07-22) [2015-06]. https://clinicaltrials.gov/ct2/show/NCT01327014?term=xuezhikang&rank=3.
  • 8Gruenwald J. The global herbs & botanicals market[EB/OL].[2015-06]. https://www.otciq.com/otciq/ajax/show FinancialReportById.pdf?id=27951.
  • 9IBM模仿人脑打造有“思考能力”的芯片[J].电脑编程技巧与维护,2014(17).
  • 10王毅.基于仿人机器人的人机交互与合作研究[D].北京科技大学,2014.

共引文献241

同被引文献83

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部